4//SEC Filing
ROSE ERIC A MD 4
Accession 0001213900-23-006181
CIK 0001814114other
Filed
Jan 29, 7:00 PM ET
Accepted
Jan 30, 9:28 PM ET
Size
16.3 KB
Accession
0001213900-23-006181
Insider Transaction Report
Form 4
ROSE ERIC A MD
Director
Transactions
- Award
Nonstatutory Stock Option (Right to Buy)
2023-01-26+23,250→ 23,250 totalExercise: $10.00Exp: 2032-08-25→ Common Stock (23,250 underlying) - Award
Nonstatutory Stock Option (Right to Buy)
2023-01-26+3,488→ 3,488 totalExercise: $4.06Exp: 2032-04-11→ Common Stock (3,488 underlying) - Award
Nonstatutory Stock Option (Right to Buy)
2023-01-26+6,975→ 6,975 totalExercise: $4.30From: 2023-01-26Exp: 2029-08-06→ Common Stock (6,975 underlying) - Award
Warrant (Right to Buy)
2023-01-26+2,325→ 2,325 totalExercise: $1.08From: 2023-01-26Exp: 2023-05-31→ Common Stock (2,325 underlying) - Award
Nonstatutory Stock Option (Right to Buy)
2023-01-26+18,600→ 18,600 totalExercise: $4.30From: 2023-01-26Exp: 2028-11-16→ Common Stock (18,600 underlying)
Footnotes (7)
- [F1]These securities were received on the closing date of the merger (the "Business Combination") contemplated by the Agreement and Plan of Merger, dated as of July 4, 2022, as amended by Amendment No. 1 thereto dated as of July 21, 2022 and Amendment No. 2 thereto dated as of November 21, 2022 (as amended, the "Merger Agreement"), by and among Orchestra BioMed Holdings, Inc. (f/k/a Health Sciences Acquisitions Corporation 2) ("HSAC2"), HSAC Olympus Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of HSAC2, and Orchestra BioMed, Inc., a Delaware corporation ("Legacy Orchestra"), in exchange for a nonstatutory stock option ("NSO") to acquire 40,000 shares of common stock of Legacy Orchestra ("Legacy Orchestra Common Stock") for $2.00 per share.
- [F2]Received in the Business Combination in exchange for a nonstatutory stock option to acquire 15,000 shares of Legacy Orchestra Common Stock for $2.00 per share.
- [F3]The nonstatutory stock options vest over a three-year period as follows: (i) 33% of the underlying shares will vest on the first anniversary of the grant date and (ii) 67% of the underlying shares will vest in equal installments on a quarterly basis, starting on the day of the month of the last month of the first quarter after the first anniversary of the grant date, that is the same day of the month as the grant date, subject to the Reporting Person's continuous service through such dates. The grant date is August 18, 2022.
- [F4]Received in the Business Combination in exchange for a nonstatutory stock option to acquire 50,000 shares of Legacy Orchestra Common Stock for $4.65 per share.
- [F5]The incentive stock options vests annually in equal installments over a two-year period starting with the first anniversary of the grant date, subject to the Reporting Person's continuous service through such date. The grant date is April 12, 2022.
- [F6]Received in the Business Combination in exchange for an incentive stock option to acquire 7,500 shares of Legacy Orchestra Common Stock for $1.89 per share.
- [F7]Received in the Business Combination in exchange for warrants to purchase 5,000 shares of Legacy Orchestra Common Stock for $0.50 per share.
Documents
Issuer
Orchestra BioMed Holdings, Inc.
CIK 0001814114
Entity typeother
Related Parties
1- filerCIK 0001139301
Filing Metadata
- Form type
- 4
- Filed
- Jan 29, 7:00 PM ET
- Accepted
- Jan 30, 9:28 PM ET
- Size
- 16.3 KB